Interestingly, SOX9 was identified as mediator of cisplatin-resistant cancer types but failed to show any impact on overall survival in a study conducted by Sun et al.[41] Furthermore, Zhou et al. could show that SOX9 expression was associated with higher tumour staging, tumour stage and higher probability of metastatic spread[42]. This evidence concerns the gene SOX9 and neoplasm.